Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYNERVA-GIMEMA phase 3 trial of PBC-driven early intensification in FLT3-mutated AML
2019-003936-21Phase 3Active
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by GIMEMA. Primary endpoint: Event-free survival at 2 years. Started Jun 2021; status: active.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2019-003936-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003936-21.